Composition: 
NEUGEM 200 mg 
Each vial contains:
Gemcitabine HCl USP eq. to Gemcitabine 200 mg.
Mannitol IP 200 mg.
Sodium acetate IP 12.5 mg.

NEUGEM 1 gm 
Each Vial contains:
Gemcitabine HCl USP eq. to Gemcitabine 1000 mg.
Mannitol IP 1000mg.
Sodium acetate IP 62.5 mg.

Indications and Usage:

First-line treatment of locally advanced or metastatic Pancreatic adenocarcinoma in patients previously treated with 5-fluorouracil; first-line treatment of locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC); Treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum- based therapy; first-line treatment of metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines are clinically contraindicated.

Unlabeled Uses 
Treatment of biliary cancer, bladder cancer, relapsed or refractory testicular cancer, squamous cell carcinoma of the head and neck.